Back to News
Market Impact: 0.3
Biodesix, Inc. Reports Third Quarter 2026 Financial Results and Revises Full-Year Revenue Guidance to $101 million to $103 million
Source: Nasdaq
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Biodesix reported third-quarter 2026 revenue of $24.0 million, up 10% year over year. Diagnostic Testing revenue rose 16% to $23.0 million. The provided article text is truncated, so no further results or outlook are available.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
BDSX0.40
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FTSE 100 today: Stocks slump as global tech rout deepens